Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 143-151 , April 2005

Radioimmunodetection and therapy of breast cancer

  • Sally J. DeNardo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Sally J. DeNardo, MD, Molecular Cancer Institute, 1508 Alhambra Blvd, Suite 3100, Sacramento, CA 95816.

References 

  1. Fisher B , Redmond C , Poisson R , et al.   Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer . N Engl J Med . 1989;320:822–828
  2. Lichter AS , Lippman ME , Danforth DNJ , et al.   Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast (A randomized trial at the National Cancer Institute) . J Clin Oncol . 1992;10:976–983
  3. Sarrazin D , Le MG , Arriagada R , et al.   Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer . Radiother Oncol . 1989;14:177–184
  4. van Dongen JA , Bartelink H , Fentiman IS , et al.   Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial . J Natl Cancer Inst . 1992;11:15–18
  5. DeNardo SJ . Radioimmunotherapy for breast cancer. Systemic tumor-targeted irradiation . Adv Oncol . 1999;15:23–29
  6. Richman CM , Schuermann TC , Wun T , et al.   Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma . Cancer . 1997;80:2728–2732
  7. Forster GJ , Santos EB , Smith-Jones PM , et al.   Localization of pancreatic tumors with CC49 single-chain antibody-streptavidin fusion protein (CC49-SA) in a multi-step-targeting (MST) approach . J Nucl Med . 2003;44:362P
  8. Sharkey RM , Karacay H , McBride W , et al.   Optimizing bispecific antibody (bsMAb) pretargeting for cancer radioimmunotherapy . J Nucl Med . 2003;44:362P
  9. Birner P , Oberhuber G , Stani J , et al.   Evaluation of the united states food and drug administration=approved scoring and test system of HER-2 protein expression in breast cancer . Clin Cancer Res . 2001;7:1669–1675
  10. Gonzalez Trotter DE , Manjeshwar RM , Doss M , et al.   Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner . J Nucl Med . 2004;45:1237–1244
  11. Kotts CE , Su FM , Leddy C , et al.   186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents (comparison of physical and biological characteristics with 125I and 131I-labeled counterparts) . Cancer Biother Radiopharm . 1996;11:133–144
  12. Robinson MR, Doss M, Shaller C, et al: Quantitative ImmunoPET imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res (in press)
  13. Olafsen T , Tan GJ , Park JM , et al.   Tumor targeting, biodistribution and micro-PET imaging of engineered anti-her2/Neu antibody fragments in xenograft-bearing mice . J Nucl Med . 2004;44:363P
  14. Esteban JM , Felder B , Ahn C , et al.   Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients . Cancer . 1994;74:1575–1583
  15. Goldenberg DM . New developments in monoclonal antibodies for cancer detection and therapy . CA Cancer J Clin . 1994;44:43–64
  16. Nabi HA . Antibody imaging in breast cancer . Semin Nucl Med . 1997;27:30–39
  17. Wong JYC , Somlo G , Odom-Maryon T , et al.   Initial results of a phase I trial evaluating 90yttrium (90Y)-chimeric T84.66 (cT84.66) anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer . Cancer Biother Radiopharm . 1998;13:314
  18. Wagener C , Yang HJ , Crawford FG , et al.   Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system (A systematic approach for the determination of epitope specificities of monoclonal antibodies) . J Immunol . 1983;130:2308–2315
  19. Neumaier M , Shively L , Chen FS , et al.   Cloning for the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human-mouse T84.66 gene in myeloma and Chinese hamster ovary cells . Cancer Res . 1990;50:2128–2134
  20. Olafsen T , Cheung CW , Yazaki PJ , et al.   Covalent disulfide-linked anti-CEA diabody allow site-specific conjugation and radiolabeling for tumor targeting applications . Protein Eng Design Selection . 2004;17:21–27
  21. Price MR , Rye PD , Petrakou E , et al.   Summary report on the ISOBM TD-4 Workshop (Analysis of 56 monoclonal antibodies against the MUC1 mucin) . Tumour Biol . 1998;19:1–20
  22. Seregni E , Coli A , Mazzucca N . Circulating tumor markers in breast cancer . Eur J Nucl Med Mol Imaging . 2004;31:S15–S22
  23. Fontenot JD , Tjandra N , Bu D , et al.   Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (MUC-1) protein core . Cancer Res . 1993;53:5386–5394
  24. Granowska M , Biassoni L , Carroll MJ , et al.   Breast cancer 99mTc SM3 radioimmunoscintigraphy . Acta Oncol . 1996;35:319–321
  25. Kramer EL , DeNardo SJ , Liebes L , et al.   Radioimmunolocalization of breast carcinoma using BrE-3 monoclonal antibody (phase I study) . J Nucl Med . 1993;34:1067–1074
  26. Baum RP , Brummendorf TH . Radioimmunolocalization of primary and metastatic breast cancer . Q. J Nucl Med . 1998;42:33–42
  27. Major PP , Dion AS , Williams CJ , et al.   Breast tumor radioimmunodetection with a 111-In-labeled monoclonal antibody (MA5) against a mucin-like antigen . Cancer Res . 1990;50:927s–931s
  28. Buckman R , De Angelis C , Shaw P , et al.   Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3 . Gynecol Oncol . 1992;47:102–109
  29. Howell LP , DeNardo SJ , Levy N , et al.   Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy (A comparative study) . Int J Biol Markers . 1995;10:126–135
  30. DeNardo SJ , Kramer EL , O’Donnell RT , et al.   Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3 (Results of a phase I clinical trial) . J Nucl Med . 1997;38:1180–1185
  31. Schrier DM , Stemmer SM , Johnson T , et al.   High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer (A phase I trial) . Cancer Res . 1995;55:5921s–5924s
  32. Cagnoni PJ , Ceriani RL , Cole WC , et al.   Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer . Cancer Biother Radiopharm . 1998;13:328
  33. Richman CM , DeNardo SJ , O’Donnell RT , et al.   Dosimetry based therapy in metastatic breast cancer patients using 90Y MAB 170H.82 with autologous stem cell support and cyclosporin A . Cancer Biother Radiopharm . 1998;13:314
  34. Kramer EL , Liebes L , Wasserheit C , et al.   Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer . Clin Cancer Res . 1998;4:1679–1688
  35. DeNardo SJ . Radioimmunotherapy in the treatment of metastatic breast cancer (an overview) . In:  Goldenberg DM editors. Cancer Therapy with Radiolabeled Antibodies . Ann Arbor, MI: CRC Press, Inc; 1995;p. 189–201
  36. McEwan AJB , MacLean GD , Hooper H , et al.   MAb 170H: 82: An evaluation of a novel panadenocarinoma monoclonal antibody labeled with 99Tcm and with 111In . Nucl Med Commun . 1992;13:11–19
  37. DeNardo SJ , Yuan A , Richman C , et al.   Therapeutic index enhancement by DOTA peptide linkage in 111In/90Y DOTA-Lym-1 and m170 MAbs in clinical trials . J Nucl Med . 2002;43:117P
  38. Albrecht H , Burke PA , Natarajan A , et al.   Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand . Bioconjug Chem . 2004;15:16–26
  39. Marken JS , Schieven GL , Hellstrom I , et al.   Cloning and expression of the tumor-associated antigen L6 . Proc Natl Acad Sci USA . 1992;89:3503–3507
  40. DeNardo SJ , Mirick GR , Kroger LA , et al.   The biologic window for chimeric L6 radioimmunotherapy . Cancer . 1994;73(suppl):1023–1032
  41. DeNardo SJ , O’Grady LF , Richman CM , et al.   Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody . Anticancer Res . 1997;17:1745–1752
  42. Richman CM , DeNardo SJ , O’Grady LF , et al.   Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions . Cancer Res . 1995;55(suppl):5916–5920
  43. Khazaeli MB , Saleh MN , Liu TP , et al.   Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans . Cancer Res . 1991;51:5461–5466
  44. Meredith RF , Khazaeli MB , Plott WE , et al.   Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer . J Nucl Med . 1992;33:23–29
  45. Meredith RF , Khazaeli MB , Liu T , et al.   Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer . J Nucl Med . 1992;33:1648–1653
  46. Schlom J , Siler K , Milenic DE , et al.   Monoclonal antibody-based therapy of a human tumor xenograft with a 177-lutetium-labeled immunoconjugate . Cancer Res . 1991;51:2889–2896
  47. Murray JL , Macey DJ , Grant EJ , et al.   Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment . Cancer Res . 1995;55:5925s–5928s
  48. Ziegler LD , Palazzolo P , Cunningham J , et al.   Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung . J Clin Oncol . 1992;10:1470–1478
  49. Sears HF , Atkinson B , Mattis J , et al.   Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors . Lancet 1 . 1982;762–765 (8275)
  50. Ledermann JA , Begent RH , Massof C , et al.   A phase I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response . Int J Cancer . 1991;47:659–664
  51. Weiden PL , Wolf SB , Breitz HB , et al.   Human anti-mouse antibody suppression with cyclosporin A . Cancer . 1994;73:1093–1097
  52. DeNardo SJ , Richman CM , Goldstein DS , et al.   Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6 (Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer) . Anticancer Res . 1997;17:1735–1744
  53. Richman CM , DeNardo SJ , O’Donnell RT , et al.   Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A . Clin Cancer Res . 1999;5:3243s–3248s
  54. Winthrop MD , DeNardo SJ , Muenzer JT , et al.   p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy . Cancer . 1997;80(suppl 12):2529–2537
  55. DeNardo SJ , Kukis DL , Miers LA , et al.   Yttrium-90-DOTA-peptide- chimeric L6 radioimmunoconjugate (Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts) . J Nucl Med . 1997;39:842–849
  56. DeNardo SJ , Kukis DL , Kroger LA , et al.   Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody (Efficacy and toxicity in breast cancer xenografts) . Proc Natl Acad Sci USA . 1997;94:4000–4004
  57. DeNardo SJ , DeNardo GL , O’Grady LF , et al.   Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies . Int J Biol Markers . 1987;2:49–53
  58. Kaminski MS , Zasadny KR , Francis IR , et al.   Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma . J Clin Oncol . 1996;14:1974–1981
  59. Bierman PJ , Vose JM , Leichner PK , et al.   Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin’s disease . J Clin Oncol . 1993;11:698–703
  60. Waldmann TA , White JD , Carrasquillo JA , et al.   Radioimmunotherapy of interleukin-2R-alpha-expressing adult T-call leukemia with Yttrium-90-labeled anti-Tac . Blood . 1995;86:4063–4075
  61. Knox SJ , Goris ML , Trisler K , et al.   Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma . Clin Cancer Res . 1996;2:457–470
  62. Press OW , Eary JF , Appelbaum FR , et al.   Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas . Lancet . 1995;346:336–340
  63. Begent RH , Ledermann JA , Green AJ , et al.   Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer . Br J Cancer . 1989;60:406–412
  64. Murray JL , Macey DJ , Kasi LP , et al.   Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer . Cancer . 1994;73:1057–1066
  65. Deb N , Goris M , Trisler K , et al.   Treatment of hormone-refractory prostate cancer with 90-Y-CYT-356 monoclonal antibody . Clin Cancer Res . 1996;2:1289–1297
  66. Stewart JS , Hird V , Snook D , et al.   Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer . J Clin Oncol . 1990;8:1441–1950

 Supported by NCI grants PO1-CA-47,829(UCD), Department of Defense Grant DAMD17 to 01-0177, and Department of Energy Grant DE-FG01 to 00NE22944.

PII: S0001-2998(04)00079-0

doi: 10.1053/j.semnuclmed.2004.12.001

Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 143-151 , April 2005

Article Tools

* Image Usage & Resolution